This study is about testing two drugs, cabozantinib and pembrolizumab, to see how well they work together against a type of cancer called adrenal cortical cancer. This cancer can spread to nearby tissues (locally advanced), move to other parts of the body (metastatic), or be in a place where surgery can't remove it (unresectable).
Cabozantinib stops certain signals that help cancer cells grow. Pembrolizumab helps the immune system fight cancer. Combining these two might work better than using each one alone.
Key Points:
- Participants take cabozantinib daily and pembrolizumab every 21 days.
- Regular check-ups, including scans and blood tests, are required throughout the study.
- The study follows participants for up to 2 years to monitor effects and safety.
Participants must be 18 or older, have adrenal cortical carcinoma, and meet specific health criteria. It's important to know that risks and benefits will be discussed, and informed consent is needed to join the study.
How understandable was the trial content above?
Hard to understand
Easy to understand